The centralized procurement of Chinese patent medicines is accelerating, and a large number of drugs will be reduced in prices in many places

[Pharmaceutical Network Industry News] The National Medical Insurance Bureau has recently made a unified deployment and coordination of the centralized procurement of local alliances, and has clarified that by the end of 2022, provinces (including inter-provincial alliances) will carry out their own centralized procurement of no less than 100 drug varieties.
, and must contain chemical drugs, proprietary Chinese medicines, orthopedic trauma, oral implants, drug balloons and other consumables
.

In this regard, the industry believes that this means that all provinces need to carry out centralized procurement of Chinese patent medicines in 2022, and the procurement of Chinese patent medicines has fully started
.

In fact, since the beginning of this year, it can be clearly found that the promotion of the policy of centralized procurement of proprietary Chinese medicines is accelerating, and the results have begun to appear
.

For example, recently, the Hainan Provincial Medical Insurance Bureau revealed that the two provincial alliances for the centralized procurement of proprietary Chinese medicines that it participated in announced the results of the successful bidding
.

Hainan Province collected a total of 151 Chinese patent medicines this time, with an average price drop of over 40%, with the highest drop of 82.
63%
.

This batch of centralized Chinese patent medicines is expected to be implemented by the end of June this year
.

 　　Before that, Hubei Alliance’s centralized procurement of proprietary Chinese medicines involved 76 major varieties, 182 products from 157 companies participated in the quotation, and the procurement scale was nearly 10 billion yuan; from the results, 97 companies and 111 products were selected, and the selection rate reached 62%, the average price dropped by 42.
27%, and the highest drop was 82.
63%
.

 　　In addition, the Guangdong Provincial Drug Trading Center also recently issued the "Notice on Viewing Information about Guangdong Alliance Qingkailing and other Chinese patent medicines for centralized procurement and registration products"
.

According to the notice, the members of the Guangdong Traditional Chinese Medicine Collective Procurement Alliance include Guangdong, Shanxi, Henan, Hainan, Ningxia, and Qinghai
.

It is reported that this centralized purchase registration covers a number of common exclusive and non-exclusive Chinese patent medicine varieties, including: Qingkailing, Lanqin, Xingnaojing, Bailing, Shengmai, Fufang Danshen, Xuesaitong, Ginkgo biloba, Kanglaite, Lianhua Qingwen, Shenkang, Tanreqing, Xiyanping
.

 　　On the whole, with the development of local pilots for the centralized procurement of Chinese patent medicines in various regions and the advancement of various medical reform policies, it has become a general trend that the pace of centralized procurement of Chinese patent medicines will continue to accelerate
.

It is worth noting that because the national centralized procurement of Chinese patent medicines and the inter-provincial alliance centralized procurement of Chinese patent medicines in China aim to win the bid for Chinese patent medicines with higher "cost-effectiveness"
.

Therefore, for most pharmaceutical companies, the policy of centralized procurement of proprietary Chinese medicines will still be a favorable policy.
Although the price will drop significantly, the expansion of the market scale will also make up for a certain loss of profits
.

 　　However, some people in the industry also pointed out that the market reshuffle will follow.
Affected by the price reduction of centralized procurement, the competition in the Chinese patent medicine market will intensify, and some Chinese medicine companies without core competitiveness may be accelerated by the times
.

It is understood that in order to enhance competitiveness and reduce the impact of centralized procurement, many Chinese patent medicine-related companies have begun to try to increase R&D investment, build standardized planting bases for Chinese medicinal materials, improve quality standards, and establish professional-level academic self-supporting promotion of traditional Chinese medicine.
Teams and other ways to enhance their competitiveness
.

For example, China Resources Sanjiu publicly stated earlier that it is studying the plan based on its own product conditions, and will pay attention to and formulate corresponding plans based on product grouping, application volume, and manufacturer competition
.